Preprint
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Registro en:
DEJNIRATTISAI, Wanwisa et al. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. bioRxiv, p. 1-64, Dec. 2021.
10.1101/2021.12.03.471045
Autor
Dejnirattisai, Wanwisa
Huo, Jiandong
Zhou, Daming
Zahradník, Jiří
Supasa, Piyada
Liu, Chang
Duyvesteyn, Helen M. E.
Ginn, Helen M.
Mentzer, Alexander J.
Tuekprakhon, Aekkachai
Nutalai, Rungtiwa
Wang, Beibei
Dijokaite, Aiste
Khan, Suman
Avinoam, Ori
Bahar, Mohammad
Skelly, Donal
Adele, Sandra
Johnson, Sile Ann
Amini, Ali
Ritter, Thomas
Mason, Chris
Dold, Christina
Pan, Daniel
Assadi, Sara
Bellass, Adam
Omo-Dare, Nikki
Koeckerling, David
Flaxman, Amy
Jenkin, Daniel
Aley, Parvinder K.
Voysey, Merryn
Clemens, Sue Ann Costa
Naveca, Felipe Gomes
Nascimento, Valdinete
Nascimento, Fernanda
Costa, Cristiano Fernandes da
Resende, Paola Cristina
Pauvolid-Correa, Alex
Siqueira, Marilda Agudo Mendonça Teixeira de
Baillie, Vicky
Serafin, Natali
Ditse, Zanele
Silva, Kelly da
Madhi, Shabir
Nunes, Marta C.
Malik, Tariq
Openshaw, Peter J. M.
Baillie, J. Kenneth
Semple, Malcolm G.
Townsend, Alain R.
Huang, Kuan-Ying A.
Tan, Tiong Kit
Carroll, Miles W.
Klenerman, Paul
Barnes, Eleanor
Dunachie, Susanna J.
Constantinides, Bede
Webster, Hermione
Crook, Derrick
Pollard, Andrew J.
Lambe, Teresa
Paterson, Neil G.
Williams, Mark A.
Hall, David R.
Fry, Elizabeth E.
Mongkolsapaya, Juthathip
Ren, Jingshan
Schreiber, Gideon
Stuart, David I.
Screaton, Gavin R.
Resumen
On the 24th November 2021 the sequence of a new SARS CoV-2 viral isolate spreading rapidly
in Southern Africa was announced, containing far more mutations in Spike (S) than previously
reported variants. Neutralization titres of Omicron by sera from vaccinees and convalescent
subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially
reduced or fail to neutralize. Titres against Omicron are boosted by third vaccine doses and
are high in cases both vaccinated and infected by Delta. Mutations in Omicron knock out or
substantially reduce neutralization by most of a large panel of potent monoclonal antibodies
and antibodies under commercial development. Omicron S has structural changes from
earlier viruses, combining mutations conferring tight binding to ACE2 to unleash evolution
driven by immune escape, leading to a large number of mutations in the ACE2 binding site
which rebalance receptor affinity to that of early pandemic viruses.